Live
Endpoints NewsAbbVie clinches FDA approval for ultra-rare blood cancer ADC from ImmunoGen purchaseFierceBiotechGSK’s hepatitis B drug cures one-fifth of patients in ‘major step’ for pervasive diseaseEndpoints NewsGSK spells out positive Phase 3 data for hepatitis B drug it licensed from IonisLabiotechLab Thread: integrating workflows to replace fragmented systemseLifeLFA-1 interaction with GBP-130 on <i>Plasmodium falciparum</i>-infected red blood cells mediates NK cell activation and parasite controleLifeComputational mechanisms for temporal integration in the anterior claustrumeLifeLanguage acquisition in newborns10x Genomics Blog10x genomics CEO Serge Saxonov sells $709,057 in shares - Investing.com10x Genomics Blog10x genomics president Hindson sells $283,399 in company stock - Investing.com10x Genomics Blog10x Genomics (NASDAQ: TXG) CEO sells 28,893 shares under 10b5-1 tax-related plan - Stock Titan10x Genomics Blog10x Genomics (TXG) officer sells 11,595 shares to cover RSU taxes - Stock TitanClinical OMICsPrecision, Gene-Edited Antimicrobial Targets Difficult-to-Treat E. Coli
Illumina Feb 27, 2026

Illumina whole-genome sequencing technology to accelerate rare disease testing in Florida - Illumina

Illumina whole-genome sequencing technology to accelerate rare disease testing in Florida - Illumina

Body unavailable. Use the original source.